Acorda Therapeutics enrolls first patient for rHIgM22 clinical trial

Mayo Clinic and Acorda Therapeutics announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis. This is a Phase 1 clinical trial enrolling people with MS to assess the safety and tolerability of rHIgM22. The study also includes several exploratory efficacy measures.